With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

New York, New York-- (Newsfile Corp. - September 15, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18 ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

16 analysts have shared their evaluations of Moderna MRNA during the recent three months, expressing a mix of bullish and ...

Moderna (MRNA) stock contnues to tumble as J.P. Morgan and Jefferies downgrade the biotech following updates at the company's ...